SCHEMBL8165609

SCHEMBL8165609

CCOc1cc(C=C2SC(=S)NC2=O)ccc1O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 4/20 1.00
PIM3 Q86V86 4/20 1.00
PIM2 Q9P1W9 4/20 1.00
DYRK1A Q13627 4/20 1.00
DYRK2 Q92630 1/20 1.00
PDE4B Q07343 6/20 0.80
PDE3A Q14432 5/20 0.80
GSK3B P49841 3/20 0.76
CISD1 Q9NZ45 3/20 0.76
CDC7 O00311 2/20 0.76
DAPK3 O43293 2/20 0.76
DYRK3 O43781 2/20 0.76
MAP4K4 O95819 2/20 0.76
RPS6KB1 P23443 2/20 0.76
CSNK1D P48730 2/20 0.76
CLK2 P49760 2/20 0.76
GSK3A P49840 2/20 0.76
NEK4 P51957 2/20 0.76
CSNK1G2 P78368 2/20 0.76
CAMK2D Q13557 2/20 0.76

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15421616 1.00 PIM1 (1.00) PIM1PIM3PIM2DYRK1ADYRK2
SCHEMBL29377541 1.00 PIM1 (1.00) PIM1PIM3PIM2DYRK1ADYRK2
SCHEMBL8165608 1.00 PIM1 (1.00) PIM1PIM3PIM2DYRK1ADYRK2
SCHEMBL1641513 0.91 DYRK1A (0.83) PIM1PIM3PIM2DYRK1ADYRK2
SCHEMBL8311863 0.91 DYRK1A (0.83) PIM1PIM3PIM2DYRK1ADYRK2
SCHEMBL8311581 0.89 PDE4B (1.00) PIM1PIM3PIM2DYRK1ADYRK2
SCHEMBL8311580 0.89 PDE4B (1.00) PIM1PIM3PIM2DYRK1ADYRK2
SCHEMBL15421525 0.89 PIM1 (1.00) PIM1PIM3PIM2DYRK1ADYRK2
SCHEMBL1250564 0.89 PIM1 (1.00) PIM1PIM3PIM2DYRK1ADYRK2
SCHEMBL1250565 0.89 PIM1 (1.00) PIM1PIM3PIM2DYRK1ADYRK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160102065-A1 NOVEL COMPOUND HAVING SKIN-WHITENING, ANTI-OXIDIZING AND PPAR ACTIVITIES AND MEDICAL USE THEREOF PUSAN NATIONAL UNIVERSITY INDUSTRY-UNIVERSITY COOPERATION FOUNDATION (KR) 2016-04-14 US claimed
US-5523314-A RHODANINE DERIVATIVES ELI LILLY AND COMPANY (US) 1996-06-04 US claimed
US-12590127-B2 Split photoactive yellow protein complementation system and uses thereof PARIS SCIENCES ET LETTRES (FR) 2026-03-31 US disclosed
WO-2024052353-A1 PROXIMITY INDUCING SYSTEM AND USES THEREOF SORBONNE UNIVERSITE (FR) 2024-03-14 WO disclosed
US-20220169682-A1 SPLIT PHOTOACTIVE YELLOW PROTEIN COMPLEMENTATION SYSTEM AND USES THEREOF PARIS SCIENCES ET LETTRES (FR) 2022-06-02 US disclosed
EP-3947355-A1 SPLIT PHOTOACTIVE YELLOW PROTEIN COMPLEMENTATION SYSTEM AND USES THEREOF Paris Sciences et Lettres (FR) 2022-02-09 EP disclosed
WO-2020201538-A1 SPLIT PHOTOACTIVE YELLOW PROTEIN COMPLEMENTATION SYSTEM AND USES THEREOF PARIS SCIENCES ET LETTRES – QUARTIER LATIN (FR) 2020-10-08 WO disclosed
EP-3719007-A1 SPLIT PHOTOACTIVE YELLOW PROTEIN COMPLEMENTATION SYSTEM AND USES THEREOF Paris Sciences et Lettres - Quartier Latin (FR) 2020-10-07 EP disclosed
US-9896421-B2 Compound having skin-whitening, anti-oxidizing and PPAR activities and medical use thereof PUSAN NATIONAL UNIVERSITY INDUSTRY-UNIVERSITY COOPERATION FOUNDATION (KR) 2018-02-20 US disclosed
US-20160102065-A1 NOVEL COMPOUND HAVING SKIN-WHITENING, ANTI-OXIDIZING AND PPAR ACTIVITIES AND MEDICAL USE THEREOF PUSAN NATIONAL UNIVERSITY INDUSTRY-UNIVERSITY COOPERATION FOUNDATION (KR) 2016-04-14 US disclosed
US-9216148-B2 Compound having skin-whitening, anti-oxidizing and PPAR activities and medical use therefor PUSAN NATIONAL UNIVERSITY INDUSTRY-UNIVERSITY COOPERATION FOUNDATION (KR) 2015-12-22 US disclosed
EP-0915090-A1 Compounds useful as hypoglycemic agents and for treating Alzheimer's disease ELI LILLY AND COMPANY (US) 1999-05-12 EP disclosed
US-5731336-A USING ARYL-SUBSTITUTED RHODAMINES ELI LILLY AND COMPANY (US) 1998-03-24 US disclosed
US-5716975-A NONTOXIC RHODANINE DERIVATIVES; ANTIDIABETIC AGENTS, CATHEPSIN D INHIBITORS, B-AMYLOID PROTEIN REDUCTION ELI LILLY AND COMPANY (US) 1998-02-10 US disclosed
US-5661168-A ADMINISTERING RHODANINE DERIVATIVES TO CONTROL DIABETES ELI LILLY AND COMPANY (US) 1997-08-26 US disclosed
WO-1996022772-A1 METHOD FOR TREATING MULTIPLE SCLEROSIS ELI LILLY AND COMPANY (US) 1996-08-01 WO disclosed
EP-0722729-A2 Aryl-substituted rhodanines for treating multiple sclerosis ELI LILLY AND COMPANY (US) 1996-07-24 EP disclosed
US-5523314-A RHODANINE DERIVATIVES ELI LILLY AND COMPANY (US) 1996-06-04 US disclosed
CN-1091006-A Chemical compound as blood sugar lowering and treatment degenerative brain disorder LILLY CO ELI (US) 1994-08-24 CN disclosed
EP-0587377-A2 Thiazolidinone derivatives as hypoglycemic agents and for treating Alzheimer's disease ELI LILLY AND COMPANY (US) 1994-03-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220169682-A1 SPLIT PHOTOACTIVE YELLOW PROTEIN COMPLEMENTATION SYSTEM AND USES THEREOF BLVRB, IK, HBG2 PIM1 4688/4885PIM3 4464/4885PIM2 4475/4885
US-20160102065-A1 NOVEL COMPOUND HAVING SKIN-WHITENING, ANTI-OXIDIZING AND PPAR ACTIVITIES AND MEDICAL USE THEREOF PPARG, PPARA, TYR PIM1 3858/4885PIM3 3936/4885PIM2 4285/4885
US-12590127-B2 Split photoactive yellow protein complementation system and uses thereof BLVRB, HBG2, Q6ZSR9 PIM1 4773/4885PIM3 4664/4885PIM2 4523/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.